Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LivaNova PLC - Ordinary Shares (NQ:LIVN)

56.66 +0.76 (+1.36%)
Streaming Delayed Price Updated: 1:54 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LivaNova PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
LivaNova to Host Investor Day on November 12, 2025
From LivaNova PLC
Via Business Wire
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
From LivaNova PLC
Via Business Wire
LivaNova Launches Essenz Perfusion System in China
From LivaNova PLC
Via Business Wire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
LivaNova to Announce Second-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
From LivaNova PLC
Via Business Wire
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Jefferies Global Healthcare Conference
From LivaNova PLC
Via Business Wire
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
From LivaNova PLC
Via Business Wire
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
From LivaNova PLC
Via Business Wire
LivaNova PLC (NASDAQ:LIVN): An Undervalued Opportunity in Medical Technology
LivaNova PLC (NASDAQ:LIVN): An Undervalued Opportunity in Medical Technology 
Via Chartmill
In a market where value is scarce, LIVANOVA PLC (NASDAQ:LIVN) offers a refreshing opportunity with its solid fundamentals.
When you look at LIVANOVA PLC (NASDAQ:LIVN), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
LivaNova to Announce First-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
NASDAQ:LIVN appears to be flying under the radar despite its strong fundamentals.
Discover LIVANOVA PLC, an undervalued stock. NASDAQ:LIVN showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Barclays Global Healthcare Conference
From LivaNova PLC
Via Business Wire
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
From LivaNova PLC
Via Business Wire
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
From LivaNova PLC
Via Business Wire
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
From LivaNova PLC
Via Business Wire
LivaNova Reports Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Appoints Susan Podlogar as a New Director
From LivaNova PLC
Via Business Wire
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
LivaNova gets Buy rating from Goldman Sachs analyst. $65 PT. The company appears poised for consistent revenue growth in its base business. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.